‘Take as needed’: New, non-addictive anxiety medication enters market

PanX, a new medication collection meant to treat anxiety disorders, has been patented and TPD LLC will oversee clinical development and commercialization efforts.

PanX is a non-addictive drug meant to be taken as it’s needed, the company said in a statement. Its ingredients include beta blockers, which interfere with adrenaline and address heart palpitations associated with anxiety, and antiemetic antimuscarinic agents, which are commonly used to treat feelings of motion sickness that stem from the central nervous system.

The drug, invented by Thomas P. Dooley, PhD, is currently available as prescription compounded pharmaceuticals, but TPD is also seeking approval from the U.S. Food and Drug Administration for some of its products.

The medication is fast-acting, so it can benefit patients who find themselves suddenly suffering from a panic attack or anxiety at random moments.

"A number of patients with prominent anxiety symptoms do not respond or cannot tolerate currently available treatments,” said Charles B. Nemeroff, MD, PhD, the chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami, in a statement. “This novel approach combining two medications with distinct mechanisms of action has the potential to fill an important niche in the management of such patients."

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”